Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Endometrial Neoplasms 14Anorexia 9Endometrial Hyperplasia 7Cachexia 7Neoplasms 5Breast Neoplasms 4Overweight 2Obesity 2Body Weight Changes 2Weight Loss 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Recurrence 1Prosthesis Failure 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Nutrition Disorders 1Neoplasms, Second Primary 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × Megestrol Acetate × Clear all
NCT04939090 2026-04-13

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
227 enrolled
Other hematologic neoplasm

Anorexia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡